Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-07-25

AUTHORS

Yoshimitsu Soga, Yoshiaki Shintani, Toshimitsu Hamasaki, Yusuke Tomoi, Junichirou Takaoka, Nobuhiro Suematsu, Hiroyoshi Yokoi, Kenji Ando, On behalf of ESPALIER Investigators

ABSTRACT

Optimal medical therapy following endovascular therapy (EVT) for femoropopliteal (FP) lesions remains unclear. Therefore, we investigated whether sarpogrelate improves primary patency after EVT for FP lesions. This study was performed as a multicenter, randomized, open-label clinical trial. 186 patients (mean age 75 ± 9 years, 78 % men) with Rutherford class 2–5 due to an FP lesion were randomly assigned to receive or not receive sarpogrelate in addition to aspirin. Primary endpoint was 1-year primary patency and the secondary endpoints were target lesion revascularization (TLR) and secondary patency. Primary patency was defined as a treated vessel without restenosis or repeat revascularization. Restenosis was defined as >2.5 of peak systolic velocity ratio. Patient, lesion, and procedural characteristics did not differ significantly between two groups (mean lesion length 156 ± 94 mm, total occlusion 35 %). Stenting was performed in 133 patients (76 %). Eighty-four (94 %) could ingest sarpogrelate during follow-up period. Primary patency was 66 % in sarpogrelate group and 56 % in non-sarpogrelate group, showing no significant difference between the groups (p = 0.33). The incidence of TLR did not differ in both groups (sarpogrelate 24 % vs non-sarpogrelate 32 %, p = 0.12). Secondary patency also did not differ (sarpogrelate 90 % vs non-sarpogrelate 92 %, p = 0.43). When the interaction of sarpogrelate with the primary patency was analyzed in previously established subgroups, no interactions were noted for any subset. Sarpogrelate did not improve primary patency after EVT for FP disease in this study. More... »

PAGES

325-332

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12928-016-0414-0

DOI

http://dx.doi.org/10.1007/s12928-016-0414-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007056021

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27456034


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angioplasty, Balloon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endovascular Procedures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Femoral Artery", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peripheral Arterial Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Popliteal Artery", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Succinates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Patency", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415432.5", 
          "name": [
            "Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soga", 
        "givenName": "Yoshimitsu", 
        "id": "sg:person.01276714415.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276714415.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Shin-Koga Hospital, Kurume, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415758.a", 
          "name": [
            "Department of Cardiology, Shin-Koga Hospital, Kurume, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shintani", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.0705554150.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705554150.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410796.d", 
          "name": [
            "Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamasaki", 
        "givenName": "Toshimitsu", 
        "id": "sg:person.01010407631.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010407631.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Shin-Koga Hospital, Kurume, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415758.a", 
          "name": [
            "Department of Cardiology, Shin-Koga Hospital, Kurume, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomoi", 
        "givenName": "Yusuke", 
        "id": "sg:person.01104331243.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104331243.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Tenyoukai Central Hospital, Kagoshima, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Cardiology, Tenyoukai Central Hospital, Kagoshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takaoka", 
        "givenName": "Junichirou", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Saiseikai Fukuoka Hospital, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415144.1", 
          "name": [
            "Department of Cardiology, Saiseikai Fukuoka Hospital, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suematsu", 
        "givenName": "Nobuhiro", 
        "id": "sg:person.0775546066.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775546066.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Center, Fukuoka Sanno Hospital, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiovascular Center, Fukuoka Sanno Hospital, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokoi", 
        "givenName": "Hiroyoshi", 
        "id": "sg:person.01052603744.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415432.5", 
          "name": [
            "Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ando", 
        "givenName": "Kenji", 
        "id": "sg:person.01014341104.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014341104.13"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "On behalf of ESPALIER Investigators", 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-07-25", 
    "datePublishedReg": "2016-07-25", 
    "description": "Optimal medical therapy following endovascular therapy (EVT) for femoropopliteal (FP) lesions remains unclear. Therefore, we investigated whether sarpogrelate improves primary patency after EVT for FP lesions. This study was performed as a multicenter, randomized, open-label clinical trial. 186 patients (mean age 75\u00a0\u00b1\u00a09\u00a0years, 78\u00a0% men) with Rutherford class 2\u20135 due to an FP lesion were randomly assigned to receive or not receive sarpogrelate in addition to aspirin. Primary endpoint was 1-year primary patency and the secondary endpoints were target lesion revascularization (TLR) and secondary patency. Primary patency was defined as a treated vessel without restenosis or repeat revascularization. Restenosis was defined as\u00a0>2.5 of peak systolic velocity ratio. Patient, lesion, and procedural characteristics did not differ significantly between two groups (mean lesion length 156\u00a0\u00b1\u00a094\u00a0mm, total occlusion 35\u00a0%). Stenting was performed in 133 patients (76\u00a0%). Eighty-four (94\u00a0%) could ingest sarpogrelate during follow-up period. Primary patency was 66\u00a0% in sarpogrelate group and 56\u00a0% in non-sarpogrelate group, showing no significant difference between the groups (p\u00a0=\u00a00.33). The incidence of TLR did not differ in both groups (sarpogrelate 24\u00a0% vs non-sarpogrelate 32\u00a0%, p\u00a0=\u00a00.12). Secondary patency also did not differ (sarpogrelate 90\u00a0% vs non-sarpogrelate 92\u00a0%, p\u00a0=\u00a00.43). When the interaction of sarpogrelate with the primary patency was analyzed in previously established subgroups, no interactions were noted for any subset. Sarpogrelate did not improve primary patency after EVT for FP disease in this study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12928-016-0414-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1042779", 
        "issn": [
          "1868-4300", 
          "1868-4297"
        ], 
        "name": "Cardiovascular Intervention and Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "keywords": [
      "target lesion revascularization", 
      "primary patency", 
      "endovascular therapy", 
      "secondary patency", 
      "FP lesions", 
      "incidence of TLR", 
      "open-label clinical trial", 
      "peak systolic velocity ratio", 
      "optimal medical therapy", 
      "Rutherford class 2", 
      "femoropopliteal artery disease", 
      "systolic velocity ratio", 
      "lesion revascularization", 
      "sarpogrelate group", 
      "primary endpoint", 
      "secondary endpoints", 
      "femoropopliteal lesions", 
      "medical therapy", 
      "artery disease", 
      "endovascular treatment", 
      "clinical trials", 
      "procedural characteristics", 
      "FP disease", 
      "sarpogrelate", 
      "patency", 
      "lesions", 
      "revascularization", 
      "significant differences", 
      "patients", 
      "restenosis", 
      "therapy", 
      "disease", 
      "endpoint", 
      "class 2", 
      "group", 
      "multicenter", 
      "stenting", 
      "aspirin", 
      "follow", 
      "incidence", 
      "trials", 
      "study", 
      "subgroups", 
      "treatment", 
      "vessels", 
      "subset", 
      "period", 
      "differences", 
      "velocity ratio", 
      "addition", 
      "effectiveness", 
      "ratio", 
      "interaction", 
      "characteristics"
    ], 
    "name": "Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study", 
    "pagination": "325-332", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007056021"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12928-016-0414-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27456034"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12928-016-0414-0", 
      "https://app.dimensions.ai/details/publication/pub.1007056021"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_702.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12928-016-0414-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12928-016-0414-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12928-016-0414-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12928-016-0414-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12928-016-0414-0'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      20 PREDICATES      94 URIs      86 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12928-016-0414-0 schema:about N081bc38041244ad394f32ca01ddd74f3
2 N0a9f9f8bdd0c4a6c9dc3fdcdf98f948e
3 N1b0215e64794423ca6d61cc6c233950d
4 N2f961a8742794d9ea9b6735c19dab33e
5 N3843460e06bf4ff186d42433857d4bae
6 N41a15d814e824e219f4cb3223e5cc224
7 N4fb2ae9ee201471d936faf4dd4656f1a
8 N738ee93884fb4c04ab918975acc40ce8
9 N9fb9c47d0d124364b259d16f4cb5c96a
10 Nacbfd9adaf4b4c2ab137ab4448397780
11 Nbb9f04084f4d477f98fd941e6ed4d75d
12 Nd9c818e5680449f8a5c08c5465be4721
13 Nd9cbf585d15b462bb82d6c929a263027
14 Nf1cb04206a5e4370823f2b0ece626d10
15 Nf2948a202b6f4a579885793535e110b9
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N786d4fe214ac40a9b83714718be06ad0
19 schema:datePublished 2016-07-25
20 schema:datePublishedReg 2016-07-25
21 schema:description Optimal medical therapy following endovascular therapy (EVT) for femoropopliteal (FP) lesions remains unclear. Therefore, we investigated whether sarpogrelate improves primary patency after EVT for FP lesions. This study was performed as a multicenter, randomized, open-label clinical trial. 186 patients (mean age 75 ± 9 years, 78 % men) with Rutherford class 2–5 due to an FP lesion were randomly assigned to receive or not receive sarpogrelate in addition to aspirin. Primary endpoint was 1-year primary patency and the secondary endpoints were target lesion revascularization (TLR) and secondary patency. Primary patency was defined as a treated vessel without restenosis or repeat revascularization. Restenosis was defined as >2.5 of peak systolic velocity ratio. Patient, lesion, and procedural characteristics did not differ significantly between two groups (mean lesion length 156 ± 94 mm, total occlusion 35 %). Stenting was performed in 133 patients (76 %). Eighty-four (94 %) could ingest sarpogrelate during follow-up period. Primary patency was 66 % in sarpogrelate group and 56 % in non-sarpogrelate group, showing no significant difference between the groups (p = 0.33). The incidence of TLR did not differ in both groups (sarpogrelate 24 % vs non-sarpogrelate 32 %, p = 0.12). Secondary patency also did not differ (sarpogrelate 90 % vs non-sarpogrelate 92 %, p = 0.43). When the interaction of sarpogrelate with the primary patency was analyzed in previously established subgroups, no interactions were noted for any subset. Sarpogrelate did not improve primary patency after EVT for FP disease in this study.
22 schema:genre article
23 schema:isAccessibleForFree false
24 schema:isPartOf N0b9338ad86bd4c71ab0d24f48164f0a1
25 N35bc66a140f04ba1816b1f564cc70dec
26 sg:journal.1042779
27 schema:keywords FP disease
28 FP lesions
29 Rutherford class 2
30 addition
31 artery disease
32 aspirin
33 characteristics
34 class 2
35 clinical trials
36 differences
37 disease
38 effectiveness
39 endovascular therapy
40 endovascular treatment
41 endpoint
42 femoropopliteal artery disease
43 femoropopliteal lesions
44 follow
45 group
46 incidence
47 incidence of TLR
48 interaction
49 lesion revascularization
50 lesions
51 medical therapy
52 multicenter
53 open-label clinical trial
54 optimal medical therapy
55 patency
56 patients
57 peak systolic velocity ratio
58 period
59 primary endpoint
60 primary patency
61 procedural characteristics
62 ratio
63 restenosis
64 revascularization
65 sarpogrelate
66 sarpogrelate group
67 secondary endpoints
68 secondary patency
69 significant differences
70 stenting
71 study
72 subgroups
73 subset
74 systolic velocity ratio
75 target lesion revascularization
76 therapy
77 treatment
78 trials
79 velocity ratio
80 vessels
81 schema:name Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study
82 schema:pagination 325-332
83 schema:productId N38087721850642f9925730e54b13410a
84 N459488d1c2794ce7983227e87b12ab42
85 N65fe8f5721fc4e77a1daf2676ef8c439
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007056021
87 https://doi.org/10.1007/s12928-016-0414-0
88 schema:sdDatePublished 2022-10-01T06:42
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N219d6f478ce34c859088848395c4dfcc
91 schema:url https://doi.org/10.1007/s12928-016-0414-0
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N081bc38041244ad394f32ca01ddd74f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Vascular Patency
97 rdf:type schema:DefinedTerm
98 N0a9f9f8bdd0c4a6c9dc3fdcdf98f948e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Platelet Aggregation Inhibitors
100 rdf:type schema:DefinedTerm
101 N0b9338ad86bd4c71ab0d24f48164f0a1 schema:volumeNumber 32
102 rdf:type schema:PublicationVolume
103 N1618db2c46d74accb2239f90615efb71 rdf:first sg:person.01010407631.81
104 rdf:rest N6683ae02b5b04b43877d3835edce8181
105 N1b0215e64794423ca6d61cc6c233950d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Aged, 80 and over
107 rdf:type schema:DefinedTerm
108 N219d6f478ce34c859088848395c4dfcc schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N2727ae3a26504651b38cb95206cef71c rdf:first sg:person.01052603744.16
111 rdf:rest Na5c426ac2d7a46f8ada90dd9fd288f31
112 N2d920b5c77de4be4ba12c785036d1f89 rdf:first Nf62f312ffab14d7ab0429c0a5f50aacc
113 rdf:rest Nf2cb8630e0944cae9afb1fb578f51be9
114 N2f961a8742794d9ea9b6735c19dab33e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N35bc66a140f04ba1816b1f564cc70dec schema:issueNumber 4
118 rdf:type schema:PublicationIssue
119 N38087721850642f9925730e54b13410a schema:name dimensions_id
120 schema:value pub.1007056021
121 rdf:type schema:PropertyValue
122 N3843460e06bf4ff186d42433857d4bae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Femoral Artery
124 rdf:type schema:DefinedTerm
125 N41a15d814e824e219f4cb3223e5cc224 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Endovascular Procedures
127 rdf:type schema:DefinedTerm
128 N459488d1c2794ce7983227e87b12ab42 schema:name pubmed_id
129 schema:value 27456034
130 rdf:type schema:PropertyValue
131 N4fb2ae9ee201471d936faf4dd4656f1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Prospective Studies
133 rdf:type schema:DefinedTerm
134 N56a8e7edf8d447789bfbf24c363f5e9f rdf:first sg:person.0705554150.49
135 rdf:rest N1618db2c46d74accb2239f90615efb71
136 N65fe8f5721fc4e77a1daf2676ef8c439 schema:name doi
137 schema:value 10.1007/s12928-016-0414-0
138 rdf:type schema:PropertyValue
139 N6683ae02b5b04b43877d3835edce8181 rdf:first sg:person.01104331243.48
140 rdf:rest N2d920b5c77de4be4ba12c785036d1f89
141 N738ee93884fb4c04ab918975acc40ce8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 N786d4fe214ac40a9b83714718be06ad0 rdf:first sg:person.01276714415.24
145 rdf:rest N56a8e7edf8d447789bfbf24c363f5e9f
146 N9fb9c47d0d124364b259d16f4cb5c96a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Popliteal Artery
148 rdf:type schema:DefinedTerm
149 Na5c426ac2d7a46f8ada90dd9fd288f31 rdf:first sg:person.01014341104.13
150 rdf:rest Nec47dde9927d413580c7e1c21b9c27e6
151 Nacbfd9adaf4b4c2ab137ab4448397780 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 Nbb9f04084f4d477f98fd941e6ed4d75d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged
156 rdf:type schema:DefinedTerm
157 Nd9c818e5680449f8a5c08c5465be4721 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Stents
159 rdf:type schema:DefinedTerm
160 Nd9cbf585d15b462bb82d6c929a263027 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Angioplasty, Balloon
162 rdf:type schema:DefinedTerm
163 Ndde0ce6ccfb74551af48af34cbf07bf4 schema:familyName On behalf of ESPALIER Investigators
164 rdf:type schema:Person
165 Nec47dde9927d413580c7e1c21b9c27e6 rdf:first Ndde0ce6ccfb74551af48af34cbf07bf4
166 rdf:rest rdf:nil
167 Nf1cb04206a5e4370823f2b0ece626d10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Succinates
169 rdf:type schema:DefinedTerm
170 Nf2948a202b6f4a579885793535e110b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Peripheral Arterial Disease
172 rdf:type schema:DefinedTerm
173 Nf2cb8630e0944cae9afb1fb578f51be9 rdf:first sg:person.0775546066.60
174 rdf:rest N2727ae3a26504651b38cb95206cef71c
175 Nf62f312ffab14d7ab0429c0a5f50aacc schema:affiliation grid-institutes:None
176 schema:familyName Takaoka
177 schema:givenName Junichirou
178 rdf:type schema:Person
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1042779 schema:issn 1868-4297
186 1868-4300
187 schema:name Cardiovascular Intervention and Therapeutics
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01010407631.81 schema:affiliation grid-institutes:grid.410796.d
191 schema:familyName Hamasaki
192 schema:givenName Toshimitsu
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010407631.81
194 rdf:type schema:Person
195 sg:person.01014341104.13 schema:affiliation grid-institutes:grid.415432.5
196 schema:familyName Ando
197 schema:givenName Kenji
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014341104.13
199 rdf:type schema:Person
200 sg:person.01052603744.16 schema:affiliation grid-institutes:None
201 schema:familyName Yokoi
202 schema:givenName Hiroyoshi
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16
204 rdf:type schema:Person
205 sg:person.01104331243.48 schema:affiliation grid-institutes:grid.415758.a
206 schema:familyName Tomoi
207 schema:givenName Yusuke
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104331243.48
209 rdf:type schema:Person
210 sg:person.01276714415.24 schema:affiliation grid-institutes:grid.415432.5
211 schema:familyName Soga
212 schema:givenName Yoshimitsu
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276714415.24
214 rdf:type schema:Person
215 sg:person.0705554150.49 schema:affiliation grid-institutes:grid.415758.a
216 schema:familyName Shintani
217 schema:givenName Yoshiaki
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705554150.49
219 rdf:type schema:Person
220 sg:person.0775546066.60 schema:affiliation grid-institutes:grid.415144.1
221 schema:familyName Suematsu
222 schema:givenName Nobuhiro
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775546066.60
224 rdf:type schema:Person
225 grid-institutes:None schema:alternateName Cardiovascular Center, Fukuoka Sanno Hospital, Fukuoka, Japan
226 Division of Cardiology, Tenyoukai Central Hospital, Kagoshima, Japan
227 schema:name Cardiovascular Center, Fukuoka Sanno Hospital, Fukuoka, Japan
228 Division of Cardiology, Tenyoukai Central Hospital, Kagoshima, Japan
229 rdf:type schema:Organization
230 grid-institutes:grid.410796.d schema:alternateName Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan
231 schema:name Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan
232 rdf:type schema:Organization
233 grid-institutes:grid.415144.1 schema:alternateName Department of Cardiology, Saiseikai Fukuoka Hospital, Fukuoka, Japan
234 schema:name Department of Cardiology, Saiseikai Fukuoka Hospital, Fukuoka, Japan
235 rdf:type schema:Organization
236 grid-institutes:grid.415432.5 schema:alternateName Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan
237 schema:name Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan
238 rdf:type schema:Organization
239 grid-institutes:grid.415758.a schema:alternateName Department of Cardiology, Shin-Koga Hospital, Kurume, Japan
240 schema:name Department of Cardiology, Shin-Koga Hospital, Kurume, Japan
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...